Your browser doesn't support javascript.
loading
Clinical management of localized undifferentiated sinonasal carcinoma: our experience and review of the literature.
Perri, Francesco; Della Vittoria Scarpati, Giuseppina; Ionna, Franco; Longo, Francesco; Montano, Massimo; Muto, Paolo; Ravo, Vincenzo; Giuliano, Mario; Caponigro, Francesco.
Afiliação
  • Perri F; Departments of Head and Neck and Sarcoma Oncology.
  • Della Vittoria Scarpati G; Department of Medical Oncology Unit, POS SS Annunziata, Taranto, Italy.
  • Ionna F; Otolaryngology and Thyroid Surgery.
  • Longo F; Otolaryngology and Thyroid Surgery.
  • Montano M; Departments of Head and Neck and Sarcoma Oncology.
  • Muto P; Radiation Therapy, IRCCS G. Pascale.
  • Ravo V; Radiation Therapy, IRCCS G. Pascale.
  • Giuliano M; Department of Clinical Medicine and Surgery, University Federico II, Naples.
  • Caponigro F; Department of Medical and experimental Oncology, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas, USA.
Anticancer Drugs ; 30(3): 308-312, 2019 03.
Article em En | MEDLINE | ID: mdl-30779722
ABSTRACT
Undifferentiated sinonasal carcinoma (SNUC) is defined as a small round blue cell tumor that is immunohistochemically distinct from other sinonasal malignancies, such as lymphoma, mucosal melanoma, nasopharyngeal carcinoma, neuroendocrine carcinoma, and olfactory neuroblastoma. SNUCs are very aggressive malignancies, provoking quick destruction of the splanchnocranium structures. Being a very rare neoplasm, there are no prospective clinical trials assessing their treatment strategies, so lots of data are derived by small retrospective trials. Tri-modality treatments (namely those treatments which use together surgery, radiation therapy and chemotherapy) are now considered the best of care for this category of poor prognosis tumors, and whenever possible they should be employed. Despite the tri-modality treatments and the multidisciplinary management, SNUCs are characterized by poor prognosis with a median overall survival reaching 14 months. Ameliorating radiotherapy techniques and performing therapies adapted to the genetics of the disease could represent a promising strategy of therapy in the near future. In this report, we have presented our experience, describing the treatment and the prognosis of four patients seen at our Institution. Moreover, we have performed a review of the literature analyzing the now available therapy options and the possible future strategies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Seio Maxilar / Carcinoma Tipo de estudo: Prognostic_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: Anticancer Drugs Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Seio Maxilar / Carcinoma Tipo de estudo: Prognostic_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: Anticancer Drugs Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2019 Tipo de documento: Article